
Study: Subcutaneous Injectable Risperidone Improves Outcomes for Certain Patients With Schizophrenia
The trial randomized patients to receive TV-46000 once monthly, TV-46000 once every 2 months, or placebo, and found that patients had improved outcomes on TV-46000 regardless of dosing schedule.





























